US0181191075 - Common Stock
ALLENA PHARMACEUTICALS INC
NASDAQ:ALNA (9/7/2022, 7:15:20 PM)
After market: 0.0665 -0.01 (-11.33%)0.075
+0 (+3.16%)
Allena Pharmaceuticals, Inc. engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. The company is headquartered in Sudbury, Massachusetts and currently employs 21 full-time employees. The company went IPO on 2017-11-02. The firm is focused on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease (CKD) and end-stage renal disease (ESRD). The Company’s lead product candidate, reloxaliase, is an oral enzyme therapeutic developing for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate (UOx) levels and commonly associated with kidney stones, CKD and ESRD. Its second product candidate, ALLN-346, is an orally administered, novel, urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced CKD. The firm is conducting two Phase IIa studies for ALLN-346.
ALLENA PHARMACEUTICALS INC
142 -F North Road, Suite 150
Sudbury MASSACHUSETTS 02462
P: 16174674577.0
CEO: Louis Brenner
Employees: 21
Website: http://www.allenapharma.com/
Good morning! It's time for another look at the biggest pre-market stock movers as we see why shares are moving Wednesday morning!
Good morning! It's time for another dive into the biggest pre-market stock movers as we see what's affecting shares on Thursday!
Here you can normally see the latest stock twits on ALNA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: